title: Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina.
abstract: BACKGROUND
  Few published data are available on the benefits of aspirin use in patients with unstable angina (UA).
  
  
  OBJECTIVE
  Aspirin use carries a mortality benefit in a population-based cohort of patients presenting with UA.
  
  
  METHODS
  All residents of Olmsted County, Minnesota presenting to local emergency departments with acute chest pain from January 1985 through December 1992 having symptoms consistent with UA were identified through medical records. A total of 1628 patients were identified with UA and were stratified by aspirin use in-hospital and at discharge. Cardiovascular mortality and nonfatal myocardial infarction and stroke were assessed over a median of 7.5 years follow-up and all-cause mortality data over a median of 16.7 years. The mean age of patients with UA was 65 years, and 60% were men.
  
  
  RESULTS
  After a median of 7.5 years follow-up, all-cause and cardiovascular-mortality rates were lower among patients prescribed versus not prescribed aspirin on discharge. There were 949 postdischarge deaths over the median follow-up of 16.7 years. After multivariable adjustment, aspirin use at discharge was associated with a lower long-term mortality (hazard ratio 0.78; 95% confidence interval, 0.65-0.93).
  
  
  CONCLUSIONS
  Aspirin use at hospital discharge following UA is associated with a reduction in long-term mortality. This long-term study extends prior trial results from select populations to a population-based cohort.
authors.affiliation: Division of Cardiology- Department of Medicine, NYU Langone Medical Center, New York, NY, USA.
authors.forename: Louai
authors.initials: L
authors.lastname: Razzouk
authors.forename: Verghese
authors.initials: V
authors.lastname: Mathew
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Lennon
authors.forename: Ashish
authors.initials: A
authors.lastname: Aneja
authors.forename: Joshua I
authors.initials: JI
authors.lastname: Mozes
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Wiste
authors.forename: Paul
authors.initials: P
authors.lastname: Muntner
authors.forename: James H
authors.initials: JH
authors.lastname: Chesebro
authors.forename: Michael E
authors.initials: ME
authors.lastname: Farkouh
mesh_terms: D000208:Acute Disease; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D016001:Confidence Intervals; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D008910:Minnesota; D015999:Multivariate Analysis; D010351:Patient Discharge; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin